227 related articles for article (PubMed ID: 20923245)
1. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
[TBL] [Abstract][Full Text] [Related]
2. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.
Spence R; Mandagere A; Richards DB; Magee MH; Dufton C; Boinpally R
Clin Pharmacol Ther; 2010 Oct; 88(4):513-20. PubMed ID: 20811346
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.
Walker G; Mandagere A; Dufton C; Venitz J
Br J Clin Pharmacol; 2009 May; 67(5):527-34. PubMed ID: 19552747
[TBL] [Abstract][Full Text] [Related]
4. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.
Richards DB; Walker GA; Mandagere A; Magee MH; Henderson LS
J Clin Pharmacol; 2009 Jun; 49(6):719-24. PubMed ID: 19389876
[TBL] [Abstract][Full Text] [Related]
5. Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study.
Spence R; Mandagere A; Walker G; Dufton C; Boinpally R
Clin Drug Investig; 2010; 30(5):313-24. PubMed ID: 20384387
[TBL] [Abstract][Full Text] [Related]
6. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.
Cárdenas KPC; Velázquez JER; Escobar JJO; Chirinos J; Pendela M
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):611-618. PubMed ID: 32472357
[TBL] [Abstract][Full Text] [Related]
8. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
Markert C; Hellwig R; Burhenne J; Hoffmann MM; Weiss J; Mikus G; Haefeli WE
Eur J Clin Pharmacol; 2013 Oct; 69(10):1785-93. PubMed ID: 23748747
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.
Spence R; Mandagere A; Dufton C; Venitz J
J Clin Pharmacol; 2008 Dec; 48(12):1451-9. PubMed ID: 18832294
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
Venitz J; Zack J; Gillies H; Allard M; Regnault J; Dufton C
J Clin Pharmacol; 2012 Dec; 52(12):1784-805. PubMed ID: 22205719
[TBL] [Abstract][Full Text] [Related]
12. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
13. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
[TBL] [Abstract][Full Text] [Related]
14. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H
Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
18. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]